Allina Health Research is responsible for conducting clinical studies and collaborating with the community’s premier research houses to advance the treatment of our patients. We are committed to the improvement of patient care through discovery.
Allina Health Research collaborates with various health organizations through a variety of clinical trials. With the help of these partnerships, Allina Health is able to create new avenues for treatment.
With over 600 research studies to date, our experienced researchers and collaborators take pride in bettering the medical community and enhancing population health in the communities we serve.
AHCI clinical trials are available at Allina Health (Minneapolis and Coon Rapids; St. Paul temporarily on hold) and MN Oncology (Minneapolis, Coon Rapids, Fridley) unless otherwise indicated.
Sea Gen SGNTUC-025 Metastatic HER2+ Breast Cancer Study (3rd Line): Phase 2 study of tucatinib + trastuzumab deruxtecan in previously treated unresectable metastatic HER2+ breast cancer (PI Krie).
CTMX-2009-002: Phase 2, open-label study of CX-2009 as monotherapy and in combination with CX-072 in advanced TNBC with 1-2 prior lines of therapy (PI Krie).
Gilead GS-US-586-6144: Phase 2, randomized, open-label study of magrolimab in combination with nab-paclitaxel and paclitaxel versus nab-paclitaxel or paclitaxel in previously untreated mTNBC (PI Krie).
SGNLVA-001: (Part F) OPENING SOON Phase 1, open-label study to evaluate the safety and tolerability of SGN-LIV1A in patients with 1st line PD-L1 low or negative LA/mTNBC (PI Krie).
SGNLVA-002: Single arm, open-label phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab for first-line treatment of patients with unresectable LA/mTNBC; requires PD-L1 Combined Positive Score (CPS) <10 (PI Krie).
GS-US-548-5916: Phase 2 study of magrolimab combination therapy in patients with untreated metastatic or unresectable, locally recurrent HNSCC or LA/mHNSCC with at least 1-2 prior systematic treatments (PI Squillante).
LAM 001-2018 ELITE Protocol: Biospecimen collection of blood from patients with precancerous liver conditions and patients with all stages of active disease (PI Squillante).
AZ MERMAID 1 D910LC00001: Phase 3 randomized, double-blind study of adjuvant durvalumab/placebo + platinum-based chemotherapy in completely resected stage II-III NSCLC (PI Squillante).
AZ MERMAID 2 D910MC00001: Phase 3 randomized, double-blind study of durvalumab/placebo for the treatment of stage II-III NSCLC patients with minimal residual disease following surgery and curative intent therapy (PI Squillante).
AZ COMPEL: Phase 3, randomized, double-blind, placebo-controlled study of platinum plus pemetrexed chemotherapy Plus osimertinib/placebo in patients with EGFRm, LA/mNSCLC who have progressed extracranially following 1st line osimertinib therapy (PI Squillante).
Gilead GS-US-548-5918: Phase 2 study of magrolimab combination therapy in patients with mNSCLC & mSCLC with at least 1 prior line of systemic therapy (PI Squillante).
SGNS40-002: Phase 2, open-label study of SEA-CD4 in combination with carbo, pemetrexed and pembrolizumab in subjects with stage IV non-squamous NSCLC (PI Amatruda).
AZ Mantle Cell Lymphoma (MCL) SUMMIT Registry: Registry study of patients who are initiating a novel agent for MCL to assess treatment patterns, RR, PFS, and OS (PI Harder).
BMS CA224-098: Phase 3, randomized, double-blind study of adjuvant immunotherapy with relatlimab and nivolumab fixed-dose combination versus nivolumab monotherapy after complete resection of stage III-IV melanoma (PI Amatruda).
SGNS40-002: Phase 2, open-label study of SEA-CD4 in combination with pembrolizumab in subjects with relapsed/refractory or uveal melanoma (PI Amatruda).
Castle Biosciences PERSONALize CBI-2020: Study to evaluate outcomes of DecisionDx melanoma test results (PI Amatruda).
Geistlich GP-2250 1001 Pancreas Cancer Study: Phase 1 trial of GP-2250 + gemcitabine in subjects with advanced unresectable or metastatic pancreatic cancer who have progressed on FOLFIRINOX (PI Squillante).
Gilead GS-US-548-5918: Phase 2 study of magrolimab combination therapy in patients with mUC who have received 2-3 prior lines of systemic therapy (PI Squillante).
Exact Sciences ASCEND2: Biospecimen collection to detect cancers earlier through elective plasma-based CancerSEEK testing in patients >50 years (PI Squillante).
OR
AZ D967RC00001: Phase 3 open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11).
If interested in more information regarding the previous studies, please call the AHCI Research Bridgeline: 612-863-8716
No current clinical trials.
Thank you for your interest in our studies. All recruitment for studies is currently suspended due to COVID-19. Please check back for updates.
No current clinical trials.